SuperworthKeros Therapeutics EPS KROS
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$3.70
- Latest quarter, Q2 FY26
- −$1.45
- Fiscal year 2025
- $1.82
Keros Therapeutics' earnings per share was −$3.70 over the twelve months to Jun 30, 2026, down 1294% on a year earlier.
In its latest quarter, Q2 FY26, it was −$1.45.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.82 | n/a |
| FY2024 | −$5.01 | n/a |
| FY2023 | −$5.20 | n/a |
| FY2022 | −$4.15 | n/a |
| FY2021 | −$2.52 | n/a |
| FY2020 | −$6.78 | n/a |
| FY2019 | −$6.08 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.45 | n/a | −$3.70 | |
| Q1 FY26 | −$1.21 | −133% | −$3.01 | |
| Q4 FY25 | −$0.86 | n/a | $1.82 | |
| Q3 FY25 | −$0.18 | n/a | $1.54 | |
| Q2 FY25 | −$0.76 | n/a | $0.31 | |
| Q1 FY25 | $3.62 | n/a | −$0.18 | |
| Q4 FY24 | −$1.14 | n/a | −$5.01 | |
| Q3 FY24 | −$1.41 | n/a | −$5.21 | |
| Q2 FY24 | −$1.25 | n/a | −$5.13 | |
| Q1 FY24 | −$1.21 | n/a | −$5.15 | |
| Q4 FY23 | −$1.34 | n/a | −$5.20 | |
| Q3 FY23 | −$1.33 | n/a | −$4.95 |
Against its peers
Companies in Drug Manufacturers - General nearest Keros Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KROSKeros Therapeutics | −$3.70 | −1294% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| SPROSpero Therapeutics | $0.11 | |
| ABUSArbutus Biopharma | $0.78 | |
| Peer median | $0.78 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Keros Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.